GRI Bio (GRI) Competitors 0.66 +0.02 (+3.30%) (As of 11:03 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GRI vs. GLTO, SYRS, BCLI, BIOR, ABVC, CANF, EDSA, GTBP, EVOK, and ADILShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Galecto (GLTO), Syros Pharmaceuticals (SYRS), Brainstorm Cell Therapeutics (BCLI), Biora Therapeutics (BIOR), ABVC BioPharma (ABVC), Can-Fite BioPharma (CANF), Edesa Biotech (EDSA), GT Biopharma (GTBP), Evoke Pharma (EVOK), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Galecto Syros Pharmaceuticals Brainstorm Cell Therapeutics Biora Therapeutics ABVC BioPharma Can-Fite BioPharma Edesa Biotech GT Biopharma Evoke Pharma Adial Pharmaceuticals Galecto (NASDAQ:GLTO) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking. Is GLTO or GRI more profitable? Galecto's return on equity of -76.96% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -76.96% -66.59% GRI Bio N/A -289.05%-165.01% Which has preferable valuation & earnings, GLTO or GRI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$38.35M-$19.14-0.31GRI BioN/AN/A-$13.04MN/AN/A Does the MarketBeat Community believe in GLTO or GRI? Galecto received 31 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 60.38% of users gave Galecto an outperform vote. CompanyUnderperformOutperformGalectoOutperform Votes3260.38% Underperform Votes2139.62% GRI BioOutperform Votes1100.00% Underperform VotesNo Votes Which has more risk and volatility, GLTO or GRI? Galecto has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -2.04, meaning that its stock price is 304% less volatile than the S&P 500. Do institutionals and insiders hold more shares of GLTO or GRI? 14.2% of Galecto shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 11.9% of Galecto shares are owned by company insiders. Comparatively, 0.3% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate GLTO or GRI? Galecto presently has a consensus target price of $10.00, indicating a potential upside of 71.23%. Given Galecto's higher possible upside, equities research analysts plainly believe Galecto is more favorable than GRI Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer GLTO or GRI? In the previous week, GRI Bio had 1 more articles in the media than Galecto. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for Galecto. GRI Bio's average media sentiment score of 1.66 beat Galecto's score of 0.58 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galecto 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryGalecto beats GRI Bio on 6 of the 11 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E RatioN/A4.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book0.5310.306.906.33Net Income-$13.04M$153.61M$118.83M$225.93M7 Day Performance-31.24%-1.73%-1.92%-0.96%1 Month Performance-49.99%-7.26%-3.75%1.06%1 Year Performance-99.27%31.10%31.37%26.59% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio0.5649 of 5 stars0.66+3.3%N/A-99.3%$1.93MN/A0.001News CoveragePositive NewsGLTOGalecto3.1146 of 5 stars$5.84+0.5%$10.00+71.2%-60.6%$7.71MN/A0.0040Gap UpSYRSSyros Pharmaceuticals4.0805 of 5 stars$0.27-5.4%$3.33+1,114.8%-89.9%$7.36M$9.94M-0.10120Analyst RevisionBCLIBrainstorm Cell Therapeutics4.4474 of 5 stars$1.29+2.4%$30.00+2,225.6%-53.4%$7.35MN/A0.0040Analyst UpgradePositive NewsBIORBiora Therapeutics2.5866 of 5 stars$1.63+0.3%$23.00+1,315.4%-87.9%$7.35MN/A0.00120Analyst ForecastABVCABVC BioPharma0.751 of 5 stars$0.55-3.1%N/A-66.4%$7.14M$150,000.00-0.6630Gap UpCANFCan-Fite BioPharma1.8668 of 5 stars$2.01flat$18.00+795.5%-1.7%$7.12M$740,000.000.008Analyst DowngradeNews CoverageEDSAEdesa Biotech3.1435 of 5 stars$2.10-4.5%$21.00+900.0%-27.9%$6.83MN/A0.0020Gap DownGTBPGT Biopharma0.0716 of 5 stars$3.05-4.4%N/A-54.2%$6.80MN/A0.008EVOKEvoke Pharma0.0506 of 5 stars$4.55-0.2%N/A-69.5%$6.78M$5.18M-0.414Analyst ForecastADILAdial Pharmaceuticals2.4942 of 5 stars$1.02flat$8.00+684.3%-50.5%$6.54MN/A0.0020 Related Companies and Tools Related Companies GLTO Alternatives SYRS Alternatives BCLI Alternatives BIOR Alternatives ABVC Alternatives CANF Alternatives EDSA Alternatives GTBP Alternatives EVOK Alternatives ADIL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
